New antiepileptic agents: Structure-activity relationships

Medicinal Chemistry Research

Volumn 21, Issue 7, 2012, Pages 1491-1508

  Banerjee, Pooja S ^a   Sharma, P K ^b  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

^b MEERUT INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

Author keywords

AED's; Anticonvulsant agents; Structure activity relationships

Indexed keywords

2 PIPERIDINECARBOXYAMIDE DERIVATIVE; 3,3,3 TRIFLUORO 2 HYDROXY 2 PHENYL-PROPIONAMIDE; 5 ADAMANTYLCARBOXAMIDO SULFONAMIDE; 5 PIVALOYLAMIDO1,3,4 THIADIAZOLE 2 SULFONAMIDE; ALKANOLAMIDE; ALPHA(BENZYLAMINO)GAMMA HYDROXYBUTYRIC ACID; ANTICONVULSIVE AGENT; ARYLPIPERAZINE DERIVATIVE; BREVIRACETAM; CARABERSAT; COMPOUND 270664; DENZIMOL; HYDROXYAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; ISATIN DERIVATIVE; LACTAM DERIVATIVE; N (2 CHLOROBENZYLAMIDE); N BENZYLAMIDE; PIPERAZINE; PYRIDAZINONE DERIVATIVE; SULFONAMIDE; THIADIAZOLE DERIVATIVE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; VIGABATRIN; XANTHONE DERIVATIVE;

ANTICONVULSANT ACTIVITY; BINDING AFFINITY; DRUG BINDING SITE; DRUG EFFECT; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG POTENCY; LIPOPHILICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 84861863732     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9615-3     Document Type: Review

References (136)

1. Alexander MS, Stables JP, Ciechanowicz-Rutkowska M, Hursthouse MB, Hibbs DE, Edafiogho IO, Moore VA, Scott KR (1996) Spiranes 6. Ring A homologues of N-benzyloxy-2-azaspiro [4,4]nonane-1,3-dione. Synthesis, X-ray analysis and anticonvulsant evaluation. Eur J Med Chem 31:787-795
2. Andurkar SV, Stables JP, Kohn H (1999) The anticonvulsant activities of N-benzyl-3-methoxypropionamides. Bioorg Med Chem 7:2381-2389
3. Andurkar SV, Beguin C, Stables JP, Kohn H (2001) Synthesis and structural studies of aza analogues of functionalized amino acids: New anticonvulsant agents. J Med Chem 44:1475-1478
4. Auberson YP (2001) Competitive AMPA antagonism: a novel mechanism for antiepileptic drugs? Drugs Fut 26:463-471
5. Austin NE, Hadley MS, Harling JD, Harrington FP, Macdonald GJ, Mitchell DJ, Riley GJ, Stean TO, Stemp G, Stratton SC, Thompson M, Upton N (2003) The design of 8,8-dimethyl[1,6] naphthyridines as potential anticonvulsant agents. Bioorg Med Chem Lett 13:1627-1629
6. Bardel P, Bolanos A, Kohn H (1994) Synthesis and anticonvulsant activities of α-acetamido-N-benzylacetamide derivatives containing an electron-deficient α-heteroaromatic substituent. J Med Chem 37:4567-4571
7. Bauer J, Reuber M (2003) Medical treatment of epilepsy. Expert Opin Emerg Drugs 8:457-467
8. Beguin C, Andurkar SV, Jin AY, Stables JP, Weaver DF, Kohn H (2003) Functionalized amido ketones: new anticonvulsant agents. Bioorg Med Chem 11:4275-4285
9. Beguin C, LeTiran A, Stables JP, Voyksner RD, Kohn H (2004) N-Substituted amino acid N′-benzylamides: synthesis, anticonvulsant, and metabolic activities. Bioorg Med Chem 12:3079-3096
10. Bell GS, Sander JW (2002) The epidemiology of epilepsy: the size of the problem. Seizure 11(Suppl A):306-314
11. Berk M, Segal J, Janet L, Vorster M (2001) Emerging options in the treatment of bipolar disorders. Drugs 61:1407-1414
12. Bickerdike MJ (2003) 5-HT2C receptor agonists as potential drugs for the treatment of obesity. Curr Top Med Chem 3:885-897
13. Bihzad S, Al-Zaid B, Edafiogho IO (2002) Phthalimidooxy compound (E49) as a potential anticancer agent. Seventh Annual Health Sciences Poster Day, p 181
14. Bishop MJ, Nilsson BM (2003) New 5-HT2C-receptor agonist expert opinion. Ther Patent 13:1691-1705
15. Blackburn TP, Buckingham RE, Chan WN, Evans JM, Hadley MS, Thompson M, Upton N, Stean TO, Stemp G, Vong AK (1995) Stereochemical differentiation of anticonvulsant and antihypertensive effects in (4-fluorobenzoylamino)- benzopyrans. Bioorg Med Chem Lett 5:1163-1166
16. Brazil CW, Pedly TA (1998) Advances in the medical treatment of epilepsy. Ann Rev Med 49:135-162
17. Brouillette WJ, Grunewald GL (1984) Synthesis and anticonvulsant activity of some substituted lactams and amides. J Med Chem 27:202-206
18. Brown TR, Holmes GL (2001) Epilepsy. New Engl J Med 344:1145-1151
19. Brown MLZCC, Van Dyke CC, Brown GB, Brouillette WJ (1999) Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem 42:1537-1545
20. Bruno-Blanch L, Galvez J, Garcia-Domenech R (2003) Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity. Bioorg Med Chem Lett 13:2749-2754
21. Chan WN, Upton N, Vong AK (1996) Synthesis of novel trans-4-(substituted- benzamido)-3,4-dihydro-2H-benzo[b]pyran-3-ol derivatives as potential anticonvulsant agents with a distinctive binding profile. J Med Chem 39:4537-4539
22. Chapleo CB, Mayer M, Myer PL, Saville JF, Smith ACB, Stilling MR, Tulloch IF, Walter DS, Welbourn AP (1986) Substituted 1,3,4-thiadiazoles with anticonvulsant activity. 1 Hydrazines. J Med Chem 29:2273-2280
23. ChF Zorumski, Mennerick S, Isenberg KE, Covey DF (2000) Potential clinical uses of neuroactive steroids. Curr Opin Invest Drugs 1:360-369
24. Choi D, Stables JP, Kohn H (1996) Synthesis and anticonvulsant activities of N-benzyl-2-acetamidopropionamide derivatives. J Med Chem 39:1907-1916
25. Conley JD, Kohn H (1987) Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy. J Med Chem 30:567-574
26. Cosford NDP, McDonald IA, Schweiger EJ (1998) Recent progress in antiepileptic drug research. In: Robertson DW (ed) Annual reports in medicinal chemistry, vol 33. Academic Press, San Diego, pp 61-70
27. Cosford NDP, Meinke PT, Stauderman KA, Hess SD (2002) Recent advances in the modulation of voltage-gated ion channels for the treatment of epilepsy. Curr Drug Targ CNS Neur Dis 1:81-104
28. Coudert P, Rubat C, Couquelet J, Fialip J, Bastide P, Privat AM (1989) Synthèse et recherche d'une activité anti-convulsivante dans une nouvelle série de diaryl-4,6 pyridazinones-3N-substituées. Eur J Med Chem 24:551-555
29. Cox DS, Scott KR, Gao H, Eddington ND (2001) Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants. J Pharm Sci 90:1540-1552
30. Cox DS, Scott KR, Gao H, Eddington ND (2002) Effect of P glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. J Pharmacol Exp Ther 302:1096-1104
31. Czuczwar SJ, Patsalos PN (2001) The new generation of GABA enhancers. CNS Drugs 15:339-350
32. Dimmock JR, Pandeya SN, Quail JW, Pugazhenthi U, Allen TM, Kao GY, Balzarini J, DeClercq E (1995a) Evaluation of the semicarbazones, thiosemicarbazones and bis-carbohydrazones of some aryl alicyclic ketones for anticonvulsant and other biological properties. Eur J Med Chem 30:303-314
33. Dimmock JR, Sidhu KK, Tumber SD, Basran SK, Chen M, Quail JW, Yang J, Rozas I, Weaver DF (1995b) Some aryl semicarbazones possessing anticonvulsant activities. Eur J Med Chem 30:287-301
34. Dimmock JR, Puthucode RN, Smith JM, Hetherington M, Quail JW, Pugazhenthi U, Lecher T, Stables JP (1996) (Aryloxy) aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen. J Med Chem 39:3984-3997
35. Dimmock JR, Vashishtha SC, Stables JP (2000a) Anticonvulsant properties of various acetylhydrazones, oxamoylhydrazones and semicarbazones derived from aromatic and unsaturated carbonyl compounds. Eur J Med Chem 35:241-248
36. Dimmock JR, Vashishtha SC, Stables JP (2000b) Ureylene anticonvulsants and related compounds. DiePharmazie 55:490-494
37. Dogan HN, Duran A, Rollas S, Sener G, Uysal MK, Gulen D (2002) Synthesis of new 2,5-disubstituted-1,3,4-thiadiazoles and preliminary evaluation of anticonvulsant and antimicrobial activities. Bioorg Med Chem 10:2893-2898
38. Duncan JS (2002) The promise of new antiepileptic drugs. Br J Clin Pharmacol 53:123-131
39. Eadie MJ (2001) Can anticonvulsant drug therapy 'cure' epilepsy? CNS Drugs 15:679-690
40. Edafiogho I, Scott KR (1996) Anticonvulsants. In: Wolff E, John ME (eds) Burger's medicinal chemistry and drug discovery. Volume 3: therapeutic agents, 5th edn. Wiley, New Jersey, pp 175-260
41. Edafiogho IO, Phillips OA, Abdel-Hamid M, Ali AAM, Matowe WC, El-Hashim A, Kombian SB (2002) Ultraviolet spectroscopy of anticonvulsant enaminones. Bioorg Med Chem 10:593-597
42. Eddington ND, Cox DS, Roberts RR, Stables JP, Powell CB, Scott KR (2000) Enaminones-versatile therapeutic pharmacophores. Further advances. Curr Med Chem 7:417-436
43. Eddington ND, Cox DS, Roberts RR, Butcher RJ, Edafiogho IO, Stables JP, Cooke N, Goodwin AM, Smith CA, Scott KR (2002) Synthesis and anticonvulsant activity of enaminones. 4. Investigation on isoxazole derivatives. Eur J Med Chem 37:635-648
44. Eddington ND, Cox DS, Khurana M, Salama NN, Stables JP, Harrison SJ, Negussie A, Taylar RS, Tran UQ, Moore JA, Barrow JC, Scott KR (2003) Synthesis and anticonvulsant activity of enaminones. Part 7. Synthesis and anticonvulsant evaluation of ethyl 4-[(substituted phenyl)amino]-6-methyl-2-oxocyclohex-3-ene- 1-carboxylates and their corresponding 5-methylcyclohex-2-enone derivatives. Eur J Med Chem 38:49-64
45. Foster JE, Nicholson JM, Butcher R, Stables JP, Edafiogho IO, Goodwin AM, Henson MC, Smith CA, Scott KR (1999) Synthesis, characterization and anticonvulsant activity of enaminones. Part 6: Synthesis of substituted vinylic benzamides as potential anticonvulsants. Bioorg Med Chem 7:2415-2425
46. Gatti G, Bonomi I, Jannuzzi G, Perucca E (2000) The new antiepileptic drugs: pharmacological and clinical aspects. Curr Pharm Des 6:839-860
47. Goel A, Madan AK (1995) Structure-activity study of antiepileptic N-aryl-isoxazolecarboxamides/N-isoxazolylbenzamide analogs using Wiener's topological index. J Struct Chem 2:155-159
48. Grimm JB, Stables JP, Brown ML (2003) Design, synthesis, and development of novel caprolactam anticonvulsants. Bioorg Med Chem 11:4133-4141
49. Hachad H, Ragueneau-Majlessi I, Levy RH (2002) New antiepileptic drugs: review on drug interactions. Ther Drug Monit 24:91-103
50. Herdon HJ, Jerman JC, Stean TO, Middlemiss DN, Chan WN, Vong AK, Evans JM, Thompson M, Upton N (1997) Characterization of the binding of [3H]-SB-204269, a radiolabelled form of the new anticonvulsant SB-204269 (carabersat), to a novel binding site in rat brain membranes. Brit J Pharmacol 121:1687-1691
51. Hinko CN, Crider AM, Kliem MA, Steinmiller CI, Seo TH, Ho B, Venkatarangan P, El-Assadi AA, Chang H, Burns CM, Tietz EI, Andersen PH, Klitgaard H (1996) Anticonvulsant activity of novel derivatives of 2- and 3 piperidinecarboxylic acid in mice and rats. Neuropharmacology 35:1721-1735
52. Ho B, Venkatarangan P, Cruse SF, Hinko CN, Andersen PH, Crider AM, Adloo AA, Roane DS, Stables JP (1998) Synthesis of 2-piperidinecarboxylic acid derivatives as potential anticonvulsants. Eur J Med Chem 33:23-31
53. Ho B, Crider AM, Stables JP (2001) Synthesis and structure-activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores. Eur J Med Chem 36:265-286
54. Ilies MA, Masereel B, Rolin S, Scozzafava A, Campeanu G, Cimpeanu V, Supuran CT (2004) Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity. Bioorg Med Chem 12:271-276
55. Isaac M (2001) The 5-HT2C receptor as a potential therapeutic target for the design of antiobesity and antiepileptic drugs. Drugs Fut 26:383-393
56. Isaac M (2005) Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs. Curr Top Med Chem 5:59-67
57. Jansen M, Dannhardt G (2003) Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions. Eur J Med Chem 38:661-670
58. Jastrzebska-Wiesek M, Librowski T, Czarnecki T, Marona H, Nowak G (2003) Central activity of new xanthone derivatives with chiral center in some pharmacological tests in mice. Pol J Pharmacol 55:461-465
59. Karolak-Wojciechowska J, Kiec-Kononowicz K, Mrozek A (2001) Structure and activity studies of glycine receptor ligands. Structural remarks on arylidene-imidazoline-4-one glycinates and glycine amides. J Mol Struct 597:73-81
60. Karolak-Wojciechowska J, Mrozek A, Kiec-Kononowicz K, Handzlik J (2003) Structure and activity studies of glycine receptor ligands. Arylidene- imidazoline-4-one amino acids. J Mol Struct 649:25-36
61. Kiec-Kononowicz K, Karolak-Wojciechowska J (1998) Structure and activity studies on glycine receptor ligands. Diphenyl imidazolin-4-one glycine amides. Acta Pol Pharm 55:389-397
62. Kiec-Kononowicz K, Karolak-Wojciechowska J, Handzlik J (1998) Glycine derivatives of imidazolones as potential ligands of glycine binding site of NMDA receptors. Acta Pol Pharm 55:381-388
63. Kim Y, Zhao L-X, Kim T-H, Je S, Kim E, Choi H, Chae W-G, Park M, Choi J, Jahng Y, Lee E-S (2000) Design and synthesis of anticonvulsive agents as 7gamma;-vinyl GABA-based potential dual acting prodrugs and their biological activities. Bioorg Med Chem Lett 10:609-613
64. Kimura Y, Hatanaka K, Naitou Y, Maeno K, Shimada I, Koakutsu A, Wanibuchi F, Yamaguchi T (2004) Pharmacological profile of YM348, a novel, potent and orally active 5-HT2Creceptor agonist. Eur J Pharmacol 483:37-43
65. Kohn H, Conley JD, Leander JD (1988) Marked stereospecificity in a new class of anticonvulsants. Brain Res 457:371-375
66. Kohn H, Sawhney KN, LeGall P, Conley JD, Robertson DW, Leander JD (1990) Preparation and anticonvulsant activity of a series of functionalized α-aromatic and α-heteroaromatic amino acids. J Med Chem 33:919-926
67. Kohn H, Sawhney KN, LeGall P, Robertson DW, Leander JD (1991) Preparation and anticonvulsant activity of a series of functionalized α- heteroaromatic-substituted amino acids. J Med Chem 34:2444-2452
68. Kohn H, Sawhney KH, Bardel P, Robertson DW, Leander JD (1993) Synthesis and anticonvulsant activities of α-heteroaromatic-αacetamido-N- benzylacetamide derivatives. J Med Chem 36: 3350-3360
69. Kohn H, Sawhney KN, Robertson DW, Leander JD (1994) Anticonvulsant properties of N-substituted α, α-diamino acid derivatives. J Pharm Sci 83:689-691
70. Kulig K, Wiȩckowski K, Wiȩckowska A, Gajda J, Pochwat B, Höfner GC, Wanner KT, Malawska B (2011) Synthesis and biological evaluation of new derivatives of 2-substituted 4-hydroxybutanamides as GABA uptake inhibitors. Eur J Med Chem 46:183-190
71. Kwan P, Brodie MJ (2000) Early identification of refractory epilepsies. New Engl J Med 342:314-319
72. Le Tiran A, Stables JP, Kohn H (2001) Functionalized amino acid anticonvulsants: synthesis and pharmacological evaluation of conformationally restricted analogues. Bioorg Med Chem 9:2693-2708
73. Le Tiran A, Stables JP, Kohn H (2002) Design and evaluation of affinity labels of functionalized amino acid anticonvulsants. J Med Chem 45:4762-4773
74. Lopes Lima JM (2000) The new drugs and strategies to manage epilepsy. Curr Pharm Des 6:873-878
75. Loscher WC (2002) Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci 23:113-118
76. Malawska B (2001) Searching of γ-amino- and γ-hydroxybutyric acid analogues with expected anticonvulsant activity. Wiad Chem 55:377-402
77. Malawska B (2003) Application of pharmacophore models for the design and synthesis of new anticonvulsant drugs. Mini Rev Med Chem 3:341-348
78. Malawska B, Antkiewicz-Michaluk L (1999) Search for new anticonvulsant compounds, Part 3. Synthesis, physicochemical properties, anticonvulsant activities and voltage-sensitive calcium channels affinity of N-substituted amides of α-(4-phenylpiperazine)-GABA. DiePharmazie 54:239-243
79. Malawska B, Gobaille S (1995) Synthesis, physicochemical and pharmacological properties of new N-substituted amides of α-piperazine- γ-hydroxybutyric acid. DiePharmazie 50:390-393
80. Malawska B, Kulig K (2008) Brivaracetam: a new drug in development for epilepsy and neuropathic pain. Exp Opin Investig Drugs 17(3):361-369
81. Malawska B, Zejc A (1995) Search for new anticonvulsant compounds. Part 1: Synthesis, physicochemical and anticonvulsant properties of new derivatives of α-amino-γ-phthalimidobutyric acid. DiePharmazie 50:722-755
82. Malawska B, Kulig K, Ciechanowicz-Rutkowska M (1997) Search for new anticonvulsant compounds. Part 2: Structure-activity relationship studies of new N-substituted amides of α-piperazinec-hydroxybutyric acid as active anticonvulsants. Arch Pharm Pharm Med Chem 330:91-99
83. Malawska B, Kulig K, Antkiewicz-Michaluk L, Cliffe I, Porter R, Misra A (1999) Anticonvulsant activities and voltage-sensitive calcium channels receptor affinity of substituted N-benzylamides of γ-amino- and γ-hydroxybutyric acid. Arch Pharm Pharm Med Chem 332:167-174
84. Malawska B, Kulig K, Bendieck E (2003) Comparison of chromatographically determined values of the lipophilicity of anticonvulsant active N-substituted amides of α-arylalkylamine-chydroxybutyric acid with values estimated by computational methods. J Planar Chromatogr 16:390-395
85. Malawska B, Kulig K, Spiewak A, Stables JP (2004) Investigation into new anticonvulsant derivatives of α-subsituted N-benzylamides of γ-hydroxy- and γ-acetoxybutyric acid. Part 5: Search for new anticonvulsant compounds. Bioorg Med Chem 12:625-632
86. Malawska B, Kulig K, Gajda J, Szczeblewski D, Musial A, Wieckowski K, Maciag D, Stables JP (2007) Design, synthesis and pharmacological evaluation of alpha-substituted N-benzylamides of gamma-hydroxybutyric acid with potential GABAergic activity. Part 6: Search for new anticonvulsant compounds. Acta Pol Pharm 64(2):127-137
87. Marona H (1998a) Evaluation of some 2-substituted derivatives of xanthone for anticonvulsant properties. DiePharmazie 53:405-409
88. Marona H (1998b) Synthesis and anticonvulsant effects of some aminoalkanolic derivatives of xanthone. DiePharmazie 53:672-676
89. Marona H, Szneler E (2003) Preliminary evaluation of anticonvulsant activity of some 4-(benzyloxy)-benzamides. Acta Pol Pharm 60: 477-480
90. Marona H, Gorka Z, Szneler E (1998) Aminoalkanolic derivatives of xanthone with potential antiepileptic activity. DiePharmazie 53:219-223
91. Marona H, Pȩkala E, Filipek B, Macie GD, Szneler E (2001) Pharmacological properties of some aminoalkanolic derivatives of xanthone. DiePharmazie 56:567-572
92. Martin L, Rabasseda X, Leeson RP, Castaner J (1999) Pregabalin. Drugs Fut 24:862-870
93. McCabe PH (2000) New anti-epileptic drugs for the 21st century. Expert Opin Pharmacother 1:633-674
94. McNamara JO (1999) Emerging Insights into the genesis of epilepsy. Nature 399:A15-A22
95. Mendyk A, Salat K, Librowski T, Czarnecki T, Malawska B (2001) Influence of new γ-aminobutyric acid amide derivatives and its pthalimide precursors on the central nervous system activity in mice. Pol J Pharmacol 53:689-693
96. Nicolson A, Leach JP (2001) Future prospects for the drug treatment of epilepsy. CNS Drugs 15:955-968
97. Obniska J, Zagorska A (2003) Synthesis and anticonvulsant properties of new N-[(4-arylpiperazin-1-yl)-methyl] derivatives of 3-aryl pyrrolidine-2,5- dione and 2-aza-spiro [4.4] nonane-1,3-dione. Farmaco 58:1227-1234
98. Obniska J, Kulig K, Zejc A (1998) Synthesis and anticonvulsant properties of new N-piperazinylalkyl imides of succinic acid. Acta Pol Pharm 55:223-231
99. Obniska J, Zejc A, Karolak-Wojciechowska J (1999) Synthesis and anticonvulsant properties of new N-pyridyl derivatives of 3-phenyland 3,3-diphenyl-succinimides. Farmaco 54:423-429
100. Obniska J, Zejc A, Zagorska A (2002) Synthesis and anticonvulsant properties of new 1-phenyl and 1-phenylamino-3-phenylpyrrolidine-2,5-dione derivatives. Acta Pol Pharm 59:209-213
101. Pandeya SN, Raja AS (2002) Synthesis of isatin semicarbazones as novel anticonvulsants-role of hydrogen. J Pharm Sci 5(3): 266-271
102. Pandeya SN, Ponnilavarasan I, Pandey A, Lakhan R, Stables JP (1999) Evaluation of p-nitrophenyl substituted semicarbazones for anticonvulsant properties. DiePharmazie 54:923-925
103. Pandeya SN, Mishra V, Ponnilavarasan I, Stables JP (2000a) Anticonvulsant activity of p-chlorophenyl substituted aryl semicarbazones - The role of primary terminal amino group. Pol J Pharmacol 52:283-290
104. Pandeya SN, Yogeeswari P, Stables JP (2000b) Synthesis and anticonvulsant activity of 4-bromophenyl substituted aryl semicarbazones. Eur J Med Chem 35:879-886
105. Pandeya SN, Manjula H, Stables JP (2001a) Design of semicarbazones and their bio-isosteric analogues as potential anticonvulsants. DiePharmazie 56:121-124
106. Pandeya SN, Sriram D, Yogeeswari P, Stables JP (2001b) Anticonvulsant and neurotoxicity evaluation of 5-(un)-substituted isatinimino derivatives. DiePharmazie 56:875-876
107. Pandeya SN, Agarwal AK, Singh A, Stables JP (2003) Design and synthesis of semicarbazones and their bio-isosteric analogues as potent anticonvulsants: the role of hydrogen bonging. Acta Pharm 53:15-24
108. Paruszewski R, Rostafinska-Suchar G, Strupinska M, Jaworski P, Stables JP (1996a) Synthesis and anticonvulsant activity of some amino acid derivatives. Part 1: Alanine derivatives. DiePharmazie 51:145-148
109. Paruszewski R, Rostafinska-Suchar G, Strupinska M, Jaworski P, Winiecka I, Stables JP (1996b) Synthesis and anticonvulsant activity of some amino acid derivatives. Part 2: Derivatives of Gly, Ala, Leu, Pro, Trp, Phe (4Cl), Ala (α-Me). DiePharmazie 51:212-215
110. Paruszewski R, Rostafinska-Suchar G, Strupinska M, Winiecka I, Stables JP (2000) Synthesis and anticonvulsant activity of some amino acid derivatives. Part 3: Derivatives of Ala, Arg, Tzl, Gly and χAbu. DiePharmazie 55:27-30
111. Paruszewski R, Strupinska M, Stables JP, Swiader M, Czuczwar S, Kleinrock Z, Turski W (2001) Amino acid derivatives with anticonvulsant activity. Chem Pharm Bull 49:629-631
112. Paruszewski R, Strupinska M, Rostafinska-Suchar G, Stables JP (2003) Anticonvulsant activity of benzylamides of some amino acids and heterocyclic acids. Prot Pept Lett 10:475-482
113. Paruszewski R, Rostafinska-Suchar G, Strupinska M, Stables JP(2004) The fourth multidisciplinary conferences on drug research, Gdańsk-Sobieszewo, Book of abstract P-129 Patsalos PN (1999) Ant-epileptic drugs: newly licensed and under development. Curr Opin Inv Drugs 1:549-562
114. Perucca E (2002) Marketed new antiepileptic drugs: are they better than old-generation agents? Ther Drug Monit 24:74-80
115. Popp FD (1984) Potential anticonvulsants. IX. Some isatin hydrazones and related compounds. J Heteroc Chem 21:1641-1645
116. Puthucode R, Pugazhenthi U, Quail JW, Stables JP, Dimmock JR (1998) Anticonvulsant activity of various aryl, arylidene and aryloxyaryl semicarbazones. Eur J Med Chem 33:595-607
117. Reddy PA, Hsiang BCH, Latifi TN, Hill MW, Woodward KE, Rothman SM, Ferrendelli JA, Covey DF (1996) 3,3-Dialkyland 3-alkyl-3-benzyl-substituted 2-pyrrolidinones: a new class of anticonvulsant agents. J Med Chem 39:1898-1906
118. Reddy PA, Woodward KE, McIlheran SM, Hsiang BCH, Latifi TN, Hill MW, Rothman SM, Ferrendelli JA, Covey DF (1997) Synthesis and anticonvulsant activities of 3,3-dialkyl- and 3-alkyl-3-benzyl-2-piperidinones (δvalerolactams) and hexahydro- 2H-azepin-2-ones (ε-caprolactams). J Med Chem 40:44-49
119. Regesta G, Tanganelli P (1999) Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 34:109-122
120. Rubat C, Coudert P, Refouvelet B, Tronche P, Bastide P, Bastide P (1990) Anticonvulsant activity of 3-oxo-5-substituted benzylidene-6-methyl-(4H)-2- pyridazinylacetamides and 2-pyridazinylacetylhydrazides. Chem Pharm Bull 38(11):3009-3013
121. Salat K, Mendyk A, Librowski T, Czarnecki R, Malawska B (2002) Influence of new γ-hydroxybutyric acid amide analogues on the central nervous system activity in mice. Pol J Pharmacol 54:731-736
122. Saxena AK, Saxena M (1995) Development in anticonvulsants. In: Jucker E (ed) Progress in drug research, vol 44. Birkhauser Verlag, Basel Boston Berlin, pp 185-291
123. Schenck HA, Lenkowski PW, Choudhury-Mukherjee I, Ko S-H, Stables JP, Patel MK, Brown ML (2004) Design, synthesis and evaluation of novel hydroxyamides as orally available anticonvulsants. Bioorg Med Chem 12:979-993
124. Shen M, Le Tiran A, Xiao Y, Golbraikh A, Kohn H, Tropsha A (2002) Quantitative structure-activity relationships analysis of functionalized amino acid anticonvulsant agents using k nearest neighbor and simulated annealing PLS methods. J Med Chem 45:2811-2823
125. Sobol E, Bialer M, Yagen B (2004) Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J Med Chem 47(17):4316-4326
126. Sridhar SK, Pandeya S, Stables JP, Ramesh A (2002) Anticonvulsant activity of hydrazones, Schiff and Mannich bases of isatin derivatives. Eur J Pharm Sc 16:129-132
127. Srivastava AVK, Kumar A (2002) Synthesis of newer thiadiazolyl and thiazolidinonyl quinazolin-4(3H)-ones as potential anticonvulsant agents. Eur J Med Chem 37:873-882
128. Srivastava AVK, Kumar A (2004) Synthesis of some newer derivatives of substituted quinazolinonyl-2-oxo/thiobarbituric acid as potent anticonvulsant agents. Bioorg Med Chem 12:1257-1264
129. Supuran CT, Mincione F, Scozzafava A, Briganti F, Mincione G, Ilies MA (1998) Carbonic anhydrase inhibitors. Metal complexes of heterocyclic sulfonamides: a new class of strong topical intraocular pressure-lowering agents with potential use as antiglaucoma drugs. Eur J Med Chem 33:247-254
130. Szelenyi I, Horvath K, Howes JF, Mazarati AM (2003) The treatment of epilepsy: future possibilities. Drugs Fut 28:925-936
131. Tan CYK, Wainman D, Weaver DF (2003) N-, α-, and β-substituted 3aminopropionic acids: design, syntheses and antiseizure activities. Bioorg Med Chem 11:113-121
132. Wiesner JB, Ugarkar BG, Castellino AJ, Barankiewicz J, Dumas DP, Gruber HE, Foster AC, Erion MD (1999) Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. J Pharmacol Exp Ther 289:1669-1677
133. Yogeeswari P, Sriram D, Sunil JLR, Kumar SS, Stables JP (2002) Anticonvulsant and neurotoxicity evaluation of some 6-chlorobenzothiazolyl-2- thiosemicarbazones. Eur J Med Chem 37: 231-236
134. Zejc A, Obniska J, Wilimowski M, Rutkowska M, Witkowski J, Barczynska L, Kedzierska-Gozdzik L, Wojewodzki W, Orzechowska-Juzwenko K, Plawiak T, Dus E, Gryska J, Gliniak M (1990) Synthesis and anticonvulsant properties of some arylsuccinate methylpyridylimides. Pol J Pharmacol Pharm 42:69-77
135. Zemp J et al (1984) Valproic acid ester with antiepileptic and anticonvulsant activity and pharmaceutical compositions there from. United States Patent 4442124
136. Zhao L-X, Park JG, Moon Y-S, Basnet A, Choi J, Kim E, Jeong TC, Jahng Y, Lee E-S (2004) Design, synthesis and anticonvulsive activity of analogs of γ-vinyl GABA. Farmaco 59:381-388